Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2010, Vol. 8 ›› Issue (1): 1-6.doi: 10.3736/jcim20100101

• Commentary •     Next Articles

Pay attention to insulin resistance in chronic liver diseases

Guang Ji   

  1. Institute of Digestive Diseases, Department of Gastroenterology of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
  • Received:2009-08-28 Accepted:2009-10-20 Online:2010-01-20 Published:2010-01-15
  • Contact: Guang Ji E-mail:jiliver@vip.sina.com

Insulin resistance exists in various chronic liver diseases such as fatty liver disease, liver cirrhosis, hepatitis, etc. Insulin resistance not only participates in the development of chronic liver diseases but also affects the efficacy of drug treatment. Paying more attention to diagnosis and treatment of insulin resistance will enhance the therapeutic effect and improve the prognosis of the patients. Traditional Chinese medicine has displayed its characteristics and advantage in treating insulin resistance. Investigation to chronic liver diseases based on lifestyle interference, exploration of the syndrome mechanism of insulin resistance, and scientific evaluation of the efficacy of Chinese herbal prescriptions will contribute to the research of traditional Chinese medicine in preventing and treating insulin resistance in chronic liver diseases.

Key words: Chronic liver disease, Insulin resistance, Traditional Chinese medicine

[1] Paul A . Nonalcoholic fatty liver disease[J]. N Engl J Med, 2002,346(16):1221-1231
doi: 10.1056/NEJMra011775
[2] Brunt EM . Nonalcoholic steatohepatitis[J]. Semin Liver Dis, 2004,24(1):3-20
[3] Bloomgarden ZT . American Association of Clinical Endocrinologists(AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC[J]. Diabetes Care, 2003,26(3):933-939
doi: 10.2337/diacare.26.3.933
[4] Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L . Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance[J]. Gut, 2004,53(7):1020-1023
doi: 10.1136/gut.2003.027086
[5] Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR . Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis[J]. Cell Metab, 2008,7(2):125-134
doi: 10.1016/j.cmet.2007.11.013
[6] Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS . Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults[J]. Arch Intern Med, 2004,164(19):2169-2175
doi: 10.1001/archinte.164.19.2169 pmid: 15505132
[7] Wada J . Vaspin: a novel serpin with insulin-sensitizing effects[J]. Expert Opin Investig Drugs, 2008,17(3):3272-3273
doi: 10.1517/13543784.17.3.327 pmid: 18321232
[8] Ye J . Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle[J]. Endocr Metab Immune Disord Drug Targets, 2007,7(1):65-74
doi: 10.2174/187153007780059423
[9] Allison ME, Wreghitt T, Palmer CR, Alexander GJ . Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population[J]. J Hepatol, 1994,21(6):1135-1139
doi: 10.1016/S0168-8278(05)80631-2
[10] Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J , O’Rahilly S, Shore S, Tom BD, Alexander GJ.Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection[J]. Hepatology, 1999,30(4):1059-1063
doi: 10.1002/(ISSN)1527-3350
[11] Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP . Association of diabetes mellitus and chronic hepatitis C virus infection[J]. Hepatology, 1999,29(2):328-333
doi: 10.1002/hep.510290235 pmid: 9918906
[12] Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A . Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection[J]. Mayo Clin Proc, 2000,75(4):355-359
doi: 10.4065/75.4.355
[13] Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M.Thomas DL . Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States[J]. Ann Intern Med, 2000,133(8):592-599
doi: 10.7326/0003-4819-133-8-200010170-00009
[14] Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL . Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J]. Gut, 2009,58(1):111-117
doi: 10.1136/gut.2008.157735 pmid: 18832522
[15] Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T, Féray C, Nicolas-Chanoine MH, Bedossa P, Marcellin P . Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C[J]. Gastroenterology, 2008,135(3):821-829
doi: 10.1053/j.gastro.2008.05.044 pmid: 18593587
[16] Tabaru A, Narita R, Hiura M, Abe S, Otsuki M . Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a[J]. Am J Gastroenterol, 2005,100(4):862-867
doi: 10.1111/ajg.2005.100.issue-4
[17] Park SH, Kim DJ, Lee HY . Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection[J]. Am J Gastroenterol, 2009,104(5):1135-1139
doi: 10.1038/ajg.2009.6
[18] Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS . Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis[J]. J Gastroenterol Hepatol, 2008,23(5):679-681
doi: 10.1111/j.1440-1746.2008.05361.x pmid: 18410599
[19] Machado MV, Cortez-Pinto H . Insulin resistance and steatosis in chronic hepatitis C[J]. Ann Hepatol, 2009,8(Suppl 1):S67-S75
doi: 10.1152/ajpgi.90298.2008 pmid: 19381127
[20] Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P . Hepatitis C virus-associated hypobeta-lipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis[J]. Am J Gastroenterol, 2003,98(5):1150-1154
[21] Demelia L, Civolani A, Murgia D, Murru A, Sorbello O, Rizzetto M . Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency[J]. J Hepatol, 2007,46(1):171-173
doi: 10.1016/j.jhep.2006.10.003
[22] Grasso A, Malfatti F, Leo PD, Martines H, Fabris P, Toscanini F, Anselmo M, Menardo G . Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin[J]. J Hepatol, 2009,51(6):984-990
doi: 10.1016/j.jhep.2009.07.008
[23] Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, Labropoulou-Karatza C . Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C[J]. Euro J Gastroenterol Hepatol, 2005,17(2):149-153
doi: 10.1097/00042737-200502000-00004
[24] Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, Nakagawa Y, Shigeno M, Miyazoe S, Ichikawa T, Ishikawa H, Nakao K, Eguchi K . Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection[J]. Cancer, 2003,97(12):2948-2950
doi: 10.1002/(ISSN)1097-0142
[25] Castéra L, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D . Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis[J]. Gut, 2004,53(3):420-424
doi: 10.1136/gut.2002.009936
[26] Fan JG . Research on fatty liver disease in 2008[J]. Zhonghua Gan Zang Bing Za Zhi, 2009,17(2):85-87
doi: 10.3760/cma.j.issn.1007-3418.2009.02.002
范建高 . 2008年脂肪性肝病研究进展[J]. 中华肝脏病杂志, 2009,17(2):85-87
doi: 10.3760/cma.j.issn.1007-3418.2009.02.002
[27] Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G . Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine[J]. J Clin Endocrinol Metab, 2008,93(7):2559-2565
doi: 10.1210/jc.2007-2404
[28] Xiao FY, Hu AM, Zheng Y, Wang JH . Effects of Tangganjian on glucose-lipid metabolism and transaminase in rats with diabetes mellitus and fatty liver disease[J]. Zhongguo Lao Nian Yi Xue Za Zhi, 2007,27(16):1560-1562
肖凤英, 胡爱明, 郑云, 王建华 . 糖肝煎对糖尿病性脂肪肝模型大鼠糖脂代谢及氨的影响[J]. 中国老年医学杂志, 2007,27(16):1560-1562
[29] He CY, Fu XD, Li B, He YM, Chen WH, Ying J, Wang WJ . Effects of “Yiqi Sanju Formula” on levels of some adipocytokines in central obese men[J]. Shanghai Zhong Yi Yao Za Zhi, 2007,41(8):16-18
何春燕, 傅晓东, 李玢, 何燕铭, 陈伟华, 应健, 王文健 . 益气散聚方对中心性肥胖男性相关脂肪细胞因子水平的影响[J]. 上海中医药杂志, 2007,41(8):16-18
[30] Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA . Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project[J]. JAMA, 2004,292(12):1433-1439
doi: 10.1001/jama.292.12.1433
[1] Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[2] Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[3] Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[4] Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[5] Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[6] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[7] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[8] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[9] Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[10] Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
[11] Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[12] Miao-yan Shi, Shi-qi Sun, Wei Zhang, Xing Zhang, Gui-hua Xu, Xuan Chen, Zi-jian Su, Xiu-ming Song, Lu-jiong Liu, Yi-bao Zhang, Yi-le Zhang, Meng Sun, Qi Chen, Yan Xue, Hua Lü, Wei-an Yuan, Xiao-rong Chen, Yun-fei Lu. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study. Journal of Integrative Medicine, 2021, 19(3): 226-231.
[13] Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[14] Yi Xia, Lu-shao-bo Shi, Jing-hui Chang, Hua-zhang Miao, Dong Wang. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior. Journal of Integrative Medicine, 2021, 19(3): 219-225.
[15] Na Zhi, Qian Mo, Shuo Yang, Yuan-xing Qin, Hao Chen, Zeng-guang Wu, Cai-hong Lan, Jun Zhang, Yin-long Li. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report. Journal of Integrative Medicine, 2021, 19(2): 185-190.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[8] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[9] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[10] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022